media – Page 190 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】Which is purer, veterinary or generic?

Drugdu.com expert’s response: The purity of veterinary drugs and generic drugs cannot be generalized, as their purity is influenced by multiple factors, including production processes, raw material quality, and quality control standards. Below is a detailed analysis of the purity of veterinary drugs and generic drugs: I. Purity of Veterinary Drugs Definition and Purpose of Veterinary Drugs: Veterinary drugs refer to substances used for preventing, treating, and diagnosing animal diseases or intentionally regulating animal physiological functions. Purity Requirements: Veterinary drugs must meet the purity requirements stipulated in the national veterinary pharmacopoeia or relevant standards. Typically, the production of veterinary drugs undergoes strict quality control, including raw material screening, production process optimization, impurity control, and other aspects, to ensure product purity. Influencing Factors: The purity of veterinary drugs can be affected by production processes, raw material quality, storage conditions, and other factors. Therefore, these factors need to be strictly controlled during ...
- Source: drugdu
- 329
- January 10, 2025
Pianzaihuang settled in the biopharmaceutical cluster in Daxing District, Beijing, with an industrial scale of 73.7 billion yuan

The reporter learned from the “Two Sessions” in Daxing District that as the “main battlefield” for the development of Beijing’s biopharmaceutical industry, Daxing District will aggregate the biopharmaceutical ecosystem and achieve remarkable results in 2024. China Medicine Valley has been selected as a “Chinese characteristic biopharmaceutical industry park”, and the six centers directly under the National Medical Products Administration have been unveiled and put into operation. Capital Medical University has started construction, and 10 chain leading enterprises such as Pianzaihuang have flocked to accelerate the construction of a comprehensive biopharmaceutical cluster, with an industrial scale of 73.7 billion yuan. Recently, the neon lights of the Pien Tze Huang Beijing Innovation and Research Base building located in the Xingchuang International Center in Daxing District began to light up. It is reported that Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (hereinafter referred to as “Pien Tze Huang Company”) is steadily advancing its ...
- Source: drugdu
- 354
- January 9, 2025
Zhengye Biotechnology, the first US listed company in Jilin Province, has landed on NASDAQ

On the evening of January 7th Beijing time, Jilin Zhengye Biological Products Co., Ltd. (referred to as “Zhengye Biotechnology”) successfully went public on the NASDAQ Stock Exchange in the United States, filling the gap for Jilin Province’s enterprises to go public in the United States. Zhengye Biotechnology is an animal vaccine manufacturer whose main business includes research and development, manufacturing, sales, and technical services of animal vaccines. The company is located in Jilin City, Jilin Province, China. Its predecessor was Harbin Veterinary Biopharmaceutical Factory of the Ministry of Agriculture, which relocated to Jilin City in 1970. It is one of the earliest veterinary biopharmaceutical enterprises directly under the Ministry of Agriculture in China, with a history of more than 50 years. In 2004, Zhengye Biotechnology was restructured from Jilin Province Biological Products Factory and is now a privately-owned joint-stock enterprise. The company’s products cover four types of animal vaccines, including ...
- Source: drugdu
- 425
- January 9, 2025
Two medical devices have entered the priority approval channel

According to the China Medical Device Innovation and Priority Approval Database, in December 2024, two medical devices entered the priority approval green channel in public announcements issued by local drug regulatory authorities across the country. They are: the disposable electronic endoscopic thoracoscopic laparoscopic catheter from Fujian Zhide Medical Technology Co., Ltd. (hereinafter referred to as Fujian Zhide), and the cognitive impairment assisted diagnosis and rehabilitation software from Hainan Boya Health Technology Co., Ltd. (hereinafter referred to as Hainan Boya). Fujian Zhide: Focusing on Endoscopy Fujian Zhide was established in April 2022 and is a company dedicated to the research and manufacturing of electronic endoscopic medical devices. The disposable 4K electronic endoscope technology developed by the research and design team of Fujian Zhide Optics has received widespread attention. This technology is both safe and convenient, not only greatly reducing the infection rate and improving cost-effectiveness, but also adapting to grassroots needs. ...
- Source: drugdu
- 259
- January 9, 2025
Innovent has made a good start

At the beginning of the new year, Innovent Biologics brought the first good news of going overseas. Recently, Innovent Biologics and Roche reached a global exclusive cooperation and licensing agreement on the new generation of DLL3 antibody-drug conjugates. Innovent Biologics granted Roche the exclusive rights to the global development, production and commercialization of IBI3009. The two parties will jointly be responsible for the early development of the ADC candidate drug, and Roche will be responsible for subsequent clinical development. Innovent Biologics will receive a total transaction amount of US$1.08 billion (including an initial payment of US$80 million and potential development and commercialization milestone payments of up to US$1 billion, as well as sales commissions). Just a few days ago, Hengrui Medicine also reached a licensing cooperation for DLL3 ADC drugs. Hengrui Medicine licensed the overseas rights of SHR-4849 to IDEAYA Biosciences of the United States for a total amount of ...
- Source: drugdu
- 329
- January 9, 2025
A battle for survival for BTK inhibitors?

Recently, Sanofi’s Rilzabrutinib was applied for listing in China for the treatment of immune thrombocytopenia (ITP). This means that the “six-strong competition” pattern in the domestic BTK inhibitor market has begun to emerge. The autoimmune BTK inhibitor market is now a place of chaos. Before Sanofi’s Rilzabrutinib was applied for listing, five BTK inhibitors had been approved in China, including AbbVie/Johnson & Johnson’s ibrutinib, AstraZeneca’s acotinib, BeiGene’s zanubrutinib, Innovent’s obeticholic steroids, and Eli Lilly’s Pirtobrutinib. The indications are mainly concentrated in hematological tumors, and only a few have been approved for autoimmune diseases. It can be seen that focusing on autoimmune indications has become a differentiated breakthrough path. Sanofi’s Rilzabrutinib is the embodiment of this strategy. The strong players in the autoimmune track are not only AbbVie and Johnson & Johnson, but also Sanofi’s strength should not be underestimated. For example, the ace product Dupixent (dupixentumab) is a “super blockbuster” ...
- Source: drugdu
- 662
- January 9, 2025
WuXi Biologics Plans to Sell Irish Vaccine Facility-Related Assets for $500 Million

On January 6, WuXi Biologics announced that the company, along with its indirect wholly-owned subsidiary WuXi Biologics Ireland, has entered into an agreement with MSD International to sell assets related to its Irish vaccine facility for $500 million. WuXi Biologics stated that the net proceeds from the asset sale will be used for the group’s operational development and general working capital for various regional operations, as well as for potential further share buybacks by the company. WuXi Biologics primarily provides comprehensive end-to-end vaccine CDMO services and acts as a global biopharmaceutical CRDMO, offering end-to-end solutions for biopharmaceutical discovery, development, and production for clients in the biopharmaceutical industry. MSD International is a subsidiary of a global pharmaceutical company that provides innovative health solutions through its prescription medicines, vaccines, biologics, and animal health products. https://finance.eastmoney.com/a/202501073289649267.html
- Source: drugdu
- 198
- January 9, 2025
Poly Pharm Faces Potential Delisting After Two Years of Fabricated Financial Performance

On January 5, Poly Pharm announced that the company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws and regulations. On January 4, the company received an “Advance Notice of Administrative Penalty” issued by the CSRC. According to the facts stated in the notice, the annual reports for 2021 and 2022 contain false records. Specifically, the fabricated operating revenue amounts to a total of 1.03 billion yuan, accounting for 31.08% of the total annual operating revenue disclosed for those two years. The total fabricated profit amounts to 695 million yuan, which constitutes 76.72% of the total annual profit disclosed for the same period. According to the facts established in the notice, Poly Pharm may engage in a significant violation that triggers mandatory delisting under the regulations of the “Shenzhen Stock Exchange’s Growth Enterprise Market Listing Rules (2024 revision),” which states that if ...
- Source: drugdu
- 392
- January 9, 2025
EXPO HOSPITAL

Organiser：FISA S.A. Exhibition Company, Santiago, Chile Time：September 9 – 11, 2025 Address：San Diego Convention Center Corporation, 111 West Harbor Drive, San Diego, CA 92101 Exhibition hall：SAN DIEGO CONVENTION CENTER Product range: Medical Devices & Equipment: Medical electronic instruments, medical ultrasonic equipment, medical X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment & materials, operating room, emergency room, and consulting room equipment & appliances, disposable medical supplies, medical dressings & hygienic materials, various surgical instruments, medical health equipment & supplies, traditional Chinese medical instruments & rehabilitation appliances, hemodialysis equipment, anesthesia & respiratory equipment, etc. Medical Consumables: Operating room, emergency room, and consulting room appliances; surgical room clothing, shoes, and gloves; various medical surgical knives, forceps, scissors; dental and bone grinding and drilling tools; microscopes, instruments and equipment; small electronic instruments; disposable items and consumables; cotton textiles; disposable syringes, blood transfusion sets, band-aids, masks, bandages, stethoscopes, toolboxes, work clothes, ...
- Source: drugdu
- 474
- January 9, 2025
【EXPERT Q&A】What qualifications do trading companies need to export apis?

Drugdu.com expert’s response: Export Requirements for Pharmaceutical Raw Materials by Trading Companies： I. Basic Qualifications Import and Export Rights: According to the relevant provisions of the “Regulations of the People’s Republic of China on the Administration of Import and Export of Goods,” foreign trade companies need to obtain import and export rights, which are the basic qualification for conducting international trade. Pharmaceutical Business License: Foreign trade companies must possess a legal pharmaceutical business license to purchase and export from domestic pharmaceutical enterprises or drug trading enterprises. If the foreign trade company itself engages in the production of pharmaceutical raw materials, it also needs to hold a valid pharmaceutical production license. Dangerous Goods Business License: Since pharmaceutical raw materials often fall into the category of dangerous goods, foreign trade companies need to hold a dangerous goods business license to comply with the “Regulations on the Administration of Safety of Dangerous Chemicals.” ...
- Source: drugdu
- 539
- January 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.